SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms
prospective open-label study, the GLP-1 RA group (liraglutide, semaglutide) continued acetazolamide at a mean dose of approximately 1000 mg, with the option to taper if headaches improved [27]
Drugs given concomitantly with narrow therapeutic windows should ensure monitoring is undertaken, especially at initiation of GLP-1 agonists when the effect is most pronounced
As such, any patient on weight loss or drugs should be very conscious of what they eat and how much they exercise
Moreover, GIP seems to attenuate GLP-1R-agonism mediated adverse effects thus making more tolerant this therapy and favoring WL
Impact on Appetite and Cravings Beyond gastric emptying, GLP-1 receptor agonists like Ozempic also act on appetite centers in the brain, helping to reduce hunger and cravings